DOLOREPIT is an interventional, RIPH 2, multicenter, randomized, controlled, open-label study comparing two care pathways for the management of patients with chronic pain.
First consultation at the pain management center
Persistence or recurrence
Duration beyond what is usual for the presumed initial cause, especially if the pain has been evolving for more than 3 months;
Inadequate response to treatment;
Patients undergoing cancer treatment or who have completed treatment within the last 2 years
Patient with a chronic inflammatory disease (e.g. rheumatoid arthritis, ankylosing spondylitis, chronic inflammatory bowel disease, Horton's disease, Wegener's disease, myositis, Still's disease, lupus erythematosus, etc.)
Immunocompromised patient
Patient with severe psychiatric pathology that does not allow study follow-up (at the discretion of the investigator)